Related Experiment Videos
Early phase II trial of human rotavirus vaccine candidate RV3
Graeme L Barnes1, Jennifer S Lund, Susan V Mitchell
1Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Melbourne, Vic. 3052, Australia. bernesg@cryptic.rch.unimelb.edu.au
Vaccine
|July 20, 2002
Summary
The rotavirus vaccine candidate RV3 showed 54% efficacy against rotavirus disease in infants who mounted an immune response. Further trials are needed to enhance the immunogenicity of this promising human rotavirus vaccine.
Area of Science:
- Virology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Rotavirus is a leading cause of severe diarrheal disease in infants globally.
- Development of safe and effective rotavirus vaccines is a public health priority.
- The naturally attenuated human neonatal rotavirus strain RV3 has shown potential as a vaccine candidate.
Purpose of the Study:
- To evaluate the safety and efficacy of the rotavirus vaccine candidate RV3 in a Phase II clinical trial.
- To assess the immunogenicity and protective efficacy of RV3 against rotavirus gastroenteritis.
Main Methods:
- A randomized, double-blind, placebo-controlled Phase II trial was conducted.
- Infants received three doses of RV3 vaccine (6.5 x 10^5 fcfu) or placebo at 3, 5, and 7 months of age.
- Immune response and protection against rotavirus disease were monitored.
Main Results:
- The RV3 vaccine was administered safely, with limited replication suggested by lack of virus excretion.
- An immune response was observed in 46% of vaccinated infants.
- Partial protection (54% efficacy) against rotavirus disease was observed in infants who developed an immune response, indicating heterotypic protection.
Conclusions:
- The rotavirus vaccine candidate RV3 demonstrated partial protective efficacy, supporting its potential.
- Strategies to improve the immunogenicity of RV3 are necessary for broader application.
- Further clinical trials are warranted to optimize this human rotavirus vaccine.